Taipei, Taiwan, October 31, 2013 --- Kyowa Hakko Kirin Taiwan Co., Ltd., (General Manager: Yu, Kuo Jung; "Kyowa Hakko Kirin Taiwan") announced today that Nplate injection has launched since October 21, 2013 (nonproprietary name: Romiplostim; referred to below as "Nplate") in Taiwan.
Nplate, a genetically recombinant protein, stimulates platelet production via stimulation of the thrombopoietin receptors. In domestic and overseas clinical trials on patients with chronic Idiopathic Thrombocytopenic Purpura (ITP) it demonstrated effectiveness for sustained platelet production and patient tolerance.
Chronic ITP is normally treated with pharmaceuticals that improve blood platelet count by suppressing platelet destruction, but Nplate serves to improve platelet counts by stimulating platelet production. With the launch of Nplate in Taiwan, Kyowa Hakko Kirin Taiwan hopes to assist patients and medical professionals by providing a new treatment option for chronic ITP.
Product summary for Nplate
Brand name
Nplate injection
Nonproprietary name
Romiplostim
Indications
Nplate is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Nplate may be considered as second line treatment for adult ITP non-splenectomised patients where surgery is contra-indicated.
Limitations of Use:
• Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP.
• Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
• Nplate should not be used in an attempt to normalize platelet counts.
Dosage and administration
Treatment should remain under the supervision of a physician who is experienced in the treatment of haematological diseases. Use the lowest dose of Nplate to achieve and maintain a platelet count
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
KYOWA KIRIN CO. LTD. 
By 
